Data contains information, and information can be used to predict future behaviors, from the buying habits of customers to securities returns. Businesses are seeking a competitive advantage by being able to use the data they hold, apply it to their unique understanding of their business domain, and then generate actionableContinue Reading
This post is co-written with Sneha Godbole and Kate Riordan from Verisk. Verisk (Nasdaq: VRSK) is a leading strategic data analytics and technology partner to the global insurance industry. It empowers its customers to strengthen operating efficiency, improve underwriting and claims outcomes, combat fraud, and make informed decisions about globalContinue Reading
2d illustrations and photos/iStock via Getty Images HashiCorp (NASDAQ:HCP) and IBM (NYSE:IBM) have acknowledged the receipt of a second request for information from the Federal Trade Commission over its antitrust probe of their merger. IBM in late April agreed to buy HashiCorp for $35 a share in cash. The twoContinue Reading
spawns Hutchmed (NASDAQ:HCM) ADRs traded higher on Friday after regulators in China agreed to review the company’s lymphoma therapy tazemetostat, developed and sold in partnership with Ipsen (OTCPK:IPSEY). China’s National Medical Products Administration (NMPA) granted priority review for the new drug application (NDA) targeting adults with relapsed or refractory (“R/R”)Continue Reading
vzphotos/iStock Editorial via Getty Images Cerevel Therapeutics (NASDAQ:CERE) quickly fell 4% amid a report about the Federal Trade Commission’s review of its sale to AbbVie. The staff of the FTC’s Mergers 1 section is said to be apparently considering a recommendation to block the Cerevel (CERE) deal, according to aContinue Reading
AstraZeneca (NASDAQ:AZN) said Monday its marketing authorization application for its investigational COVID-19 prevention drug, sipavibart, has been accepted for an accelerated assessment by the EU drug regulator. The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use granted sipavibart accelerated assessment as it was deemed of major interestContinue Reading
Grandbrothers/iStock Editorial via Getty Images Ionis Pharmaceuticals (NASDAQ:IONS) traded higher Tuesday after the U.S. FDA accepted to review a marketing application for its anti-lipid therapy olezarsen, targeted at a rare genetic condition known as familial chylomicronemia syndrome (FCA). Granting priority review for Ionis’ (IONS) New Drug Application (NDA) for olezarsen,Continue Reading
vzphotos/iStock Editorial via Getty Images Cerevel Therapeutics (NASDAQ:CERE) fell 5.5% as investors wait to hear if the Federal Trade Commission will approve its planned $8.7 billion sale to AbbVie (NYSE:ABBV). The deal spread is the widest since the transaction was announced in early December. While there was no specific reasonContinue Reading
